You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
T
Active, not recruiting
  • Lymphoma, B-Cell
  • San Antonio, Texas
    Mays Cancer Center, UT Health San Antonio
2022-03-09
Mar 9, 2022
U
T
Withdrawn
  • Lymphoma, B-Cell
  • TAC01-CD19
  • (no location specified)
2022-02-07
Feb 7, 2022
L
Not yet recruiting
  • Lymphoma, Non-Hodgkin Lymphoma, B-Cell
  • BAFF CAR-T
  • (no location specified)
2022-04-01
Apr 1, 2022
C
Not yet recruiting
  • High-grade B-cell Lymphoma
  • +8 more
  • Sepantronium Bromide
  • Busan, Korea, Republic of
  • +5 more
2022-02-27
Feb 27, 2022
H
Recruiting
  • Lymphoma, B-Cell
  • Rituximab Biosimilar
  • Pegylated Interferon α-2b
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
2022-04-06
Apr 6, 2022
U
Not yet recruiting
  • Lymphoma, B-Cell
  • CD19 redirected autologous T cells (CTL019 or CTL119 cells)
  • Philadelphia, Pennsylvania
    University of Pennsylvania
2022-03-18
Mar 18, 2022
N
Terminated
  • Lymphoma, B-Cell
  • +3 more
  • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-01-26
Jan 26, 2022
U
Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
S
Recruiting
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • +4 more
  • Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
  • R-CHOP; R-DA-EPOCH; R-HD MTX
  • Jinan, Shandong, China
    Department of Hematology, Shandong Provincial Hospital
2021-12-07
Dec 7, 2021
C
Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • +3 more
    • (no location specified)
    2021-07-20
    Jul 20, 2021
    S
    Recruiting
    • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
    • +4 more
    • Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
    • Jinan, Shandong, China
      Shandong Provincial Hospital
    2021-11-18
    Nov 18, 2021
    C
    Recruiting
    • Leukemia
    • +4 more
    • CD19 CAR-T cells
    • Kunming, Yunnan, China
      920th Hospital of Joint Logistics Support Force
    2021-03-01
    Mar 1, 2021
    U
    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    2022-02-02
    Feb 2, 2022
    I
    Recruiting
    • B-cell Non-Hodgkin's Lymphoma
    • Cincinnati, Ohio
      The Christ Hospital
    2022-04-01
    Apr 1, 2022
    I
    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
    • Toulouse, France
      Institut Universitaire du Cancer Toulouse - Oncopole
    2022-03-28
    Mar 28, 2022
    M
    Recruiting
    • Lymphoma, Non-Hodgkin
    • +4 more
      • Rochester, Minnesota
        Mayo Clinic
      2021-08-30
      Aug 30, 2021
      F
      Recruiting
      • Lymphoma, B-Cell
      • +2 more
      • Birmingham, Alabama
      • +4 more
      2021-11-23
      Nov 23, 2021
      G
      Completed
      • Non-Hodgkin's Lymphoma
      • Lymphoma, B-Cell
      • radiolabeled epratuzumab
      • (no location specified)
      2021-08-12
      Aug 12, 2021
      I
      Withdrawn
      • Diffuse Large B Cell Lymphoma
      • +3 more
      • CD19 t-haNK
      • El Segundo, California
        Chan Soon-Shiong Institute for Medicine
      2021-05-14
      May 14, 2021
      R
      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
        • (no location specified)
        2021-12-27
        Dec 27, 2021
        S
        Completed
        • Lymphoma, Large B-Cell, Diffuse
        • FDG PET radiomic feature evaluation
        • Hangzhou, Zhejiang, China
          Second Affiliated Hospital, School of Medicine, Zhejiang Univers
        2021-09-27
        Sep 27, 2021
        B
        Suspended
        • B-cell Non-Hodgkin's Lymphoma
        • CD19/CD20 Dual-CAR-T cells
        • Beijing, Beijing, China
          Beijing Tsinghua Changgung Hospital
        2022-01-29
        Jan 29, 2022
        B
        Not yet recruiting
        • Relapsed Diffuse Large B-cell Lymphoma
        • loncastuximab tesirine
        • Detroit, Michigan
          Barbara Ann Karmanos Cancer Institute
        2022-01-24
        Jan 24, 2022